VLC
VRTX icon

Van Leeuwen & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Van Leeuwen & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$6.7M Sell
16,020
-317
-2% -$134K 3.39% 5
2023
Q4 		$6.65M Sell
16,337
-34
-0.2% -$12.6K 3.87% 4
2023
Q3 		$5.69M Buy
16,371
+6,464
+65% +$2.26M 3.55% 7
2023
Q2 		$3.44M Buy
9,907
+216
+2% +$72.8K 2.16% 16
2023
Q1 		$3.05M Buy
9,691
+6,444
+198% +$1.93M 2.05% 16
2022
Q4 		$938K Buy
+3,247
New +$990K 0.65% 39
2020
Q3 		– Sell
-7,719
Closed -$2.24M – 74
2020
Q2 		$2.24M Buy
+7,719
New +$2.09M 1.74% 25

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Van Leeuwen & Company's VRTX Position: Q1 2024 in Review

Van Leeuwen & Company reduced its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q1 2024, selling an estimated $134K and leaving 16,020 shares worth $6.7M. The position accounts for 3.39% of the portfolio, ranked #5.

Van Leeuwen & Company first reported a position in VRTX in Q2 2020 and has held it in 7 quarters since. 1,494 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Van Leeuwen & Company held 16,020 shares of Vertex Pharmaceuticals worth $6.7M as of Q1 2024.
  • Van Leeuwen & Company sold 317 Vertex Pharmaceuticals shares in Q1 2024, an estimated $134K.
  • Vertex Pharmaceuticals made up 3.39% of Van Leeuwen & Company's portfolio in Q1 2024, its #5 holding.
  • Van Leeuwen & Company first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
  • 1,494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Van Leeuwen & Company's 13F filing for Q1 2024, filed 10 May 2024.